• Review • Previous Articles     Next Articles

Clinical research progresses of miRNAs in acute coronary syndrome

CAO Hui-min, XUE Xiao-mei, YOU Sha-sha, HE Bin   

  1. Department of Anesthesiology and SICU, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2016-08-29 Published:2016-08-31
  • Supported by:

    National Natural Science Foundation of China, 81470390, 81270003; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152218; Medical Engineering Cross Project of Shanghai Jiao Tong University, YG2013MS20; Funding for Clinical Trial of Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, 15LC07


The morbidity and mortality of acute coronary syndrome (ACS) are gradually increasing. Gene therapy has become a hot spot in clinical research and microRNAs (miRNAs) are novel target genes with a promising future in clinical application. For ACS, the expressions of cardiac-specific miRNAs will change in both tissues and blood such as miR-1, miR-133, miR-208, and miR-499, which may be ideal new biomarkers for early diagnosis and predicting the prognosis of ACS. miR-499 and miR-208 are particularly prospective because they only express in myocardium with high specificity. Meanwhile, miRNAs may also serve as targets of new cardiovascular drugs, which can slow down the disease progression and alleviate some symptoms via over-expressions or suppression of expressions of related miRNAs. This article reviews clinical research progresses of microRNAs in ACS.

Key words: microRNA, acute coronary syndrome, cardiovascular disease, clinical research